Clinical Trials Details

S1418-BR006 (Breast)

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor Negative Breast Cancer with = or Positive Lymph Nodes (ypN+)After Neoadjuvant Chemotherapy

Objective

This clinical trial was temporarily closed to new patient accrual on January, 22, 2021.

Clinical Trial Categories

  • Cancers and Other Neoplasms